JPWO2020106889A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020106889A5 JPWO2020106889A5 JP2021527883A JP2021527883A JPWO2020106889A5 JP WO2020106889 A5 JPWO2020106889 A5 JP WO2020106889A5 JP 2021527883 A JP2021527883 A JP 2021527883A JP 2021527883 A JP2021527883 A JP 2021527883A JP WO2020106889 A5 JPWO2020106889 A5 JP WO2020106889A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- affinity reagent
- item
- sequence
- affinity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003153 chemical reaction reagent Substances 0.000 claims description 116
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 46
- 108010067902 Peptide Library Proteins 0.000 claims description 29
- 239000000126 substance Substances 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 229920000272 Oligonucleotide Polymers 0.000 claims description 6
- 102000004965 antibodies Human genes 0.000 claims description 4
- 108090001123 antibodies Proteins 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000036462 Unbound Effects 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
Description
２４９．液状媒体が水性媒体を含む、項目２４８の親和性試薬プール。
本明細書に示す開示内容はまた、以下の項目によっても規定される：
[項目１]
各ペプチドが式αＸβの配列を含む第１の複数のペプチドを含む第１のペプチドライブラリーを得ること、式中、Ｘは所望のエピトープであり、αおよびβは、既知のアミノ酸配列を含むフランキングドメインである；
前記第１のペプチドライブラリーを複数の親和性試薬に曝露し、それにより前記複数の親和性試薬の少なくとも１つの親和性試薬を前記第１のペプチドライブラリーに結合させること；
前記第１の複数のペプチドに結合された前記少なくとも１つの親和性試薬の（１つまたは複数の）配列を決定し、それにより縮小された親和性試薬プールを形成すること；
各ペプチドが式γＸδの配列を含む第２の複数のペプチドを含む第２のペプチドライブラリーを得ること、式中、Ｘは所望のエピトープであり、γおよびδは、既知のアミノ酸配列を含むフランキングドメインである；
前記第２のペプチドライブラリーを前記縮小された親和性試薬プールに曝露し、それにより前記縮小された親和性試薬プールの少なくとも１つの親和性試薬を前記第２のペプチドライブラリーに結合させること；ならびに
前記縮小された親和性試薬プールのうち前記第２のペプチドライブラリーに結合された少なくとも１つの親和性試薬の（１つまたは複数の）配列を決定し、それにより前記エピトープＸに対する親和性試薬を同定すること
を含む、エピトープに対する親和性試薬の同定方法。
[項目２]
αおよびβが同じアミノ酸配列を含む、項目１に記載の方法。
[項目３]
αおよびβが異なるアミノ酸配列を含む、項目１に記載の方法。
[項目４]
αおよびβがγおよびδと異なるアミノ酸配列を含む、項目１に記載の方法。
[項目５]
αおよびβが、均一系化学的多様性を有するアミノ酸配列を含む、項目１に記載の方法。
[項目６]
前記均一系化学的多様性を有するアミノ酸配列が、同等の電荷、疎水性、親水性、立体的サイズ、極性、分子構造またはその組合せを有する２つまたはそれより多くのアミノ酸側鎖基を含むアミノ酸配列を含む、項目５に記載の方法。
[項目７]
αおよびβが、不均一系化学的多様性を有するアミノ酸配列を含む、項目１に記載の方法。
[項目８]
前記不均一系化学的多様性を有するアミノ酸配列が、違う電荷、疎水性、親水性、立体的サイズ、極性、分子構造またはその組合せを有する２つまたはそれより多くのアミノ酸側鎖基を含むアミノ酸配列を含む、項目７に記載の方法。
[項目９]
γおよびδが、均一系化学的多様性を有するアミノ酸配列を含む、項目１に記載の方法。
[項目１０]
前記均一系化学的多様性を有するアミノ酸配列が、同等の電荷、疎水性、親水性、立体的サイズ、極性、分子構造またはその組合せを有する２つまたはそれより多くのアミノ酸側鎖基を含むアミノ酸配列を含む、項目９に記載の方法。
[項目１１]
γおよびδが、不均一系化学的多様性を有するアミノ酸配列を含む、項目１に記載の方法。
[項目１２]
前記不均一系化学的多様性を有するアミノ酸配列が、違う電荷、疎水性、親水性、立体的サイズ、極性、分子構造またはその組合せを有する２つまたはそれより多くのアミノ酸側鎖基を含むアミノ酸配列を含む、項目１１に記載の方法。
[項目１３]
前記複数の親和性試薬のうち前記第１のペプチドライブラリーに結合された前記少なくとも１つの親和性試薬を洗浄することをさらに含む、項目１に記載の方法。
[項目１４]
前記縮小された親和性試薬プールのうち前記第２のペプチドライブラリーに結合された前記少なくとも１つの親和性試薬を洗浄することをさらに含む、項目１に記載の方法。
[項目１５]
前記第１または第２のペプチドライブラリー内の前記ペプチドがネイティブ状態である、項目１に記載の方法。
[項目１６]
前記ペプチドの第１または第２のライブラリー内の前記ペプチドが非ネイティブ状態である、項目１に記載の方法。
[項目１７]
前記非ネイティブ状態が変性状態または部分的にフォールディングされた状態である、項目１に記載の方法。
[項目１８]
前記少なくともオンの親和性試薬が１つより多くのエピトープと結合する、項目１に記載の方法。
[項目１９]
前記１つより多くのエピトープが縮重アミノ酸配列を含む、項目１８に記載の方法。
[項目２０]
前記縮重アミノ酸配列は１個のアミノ酸が異なる、項目１９に記載の方法。
[項目２１]
前記縮重アミノ酸配列は１個より多くのアミノ酸が異なる、項目１９に記載の方法。
[項目２２]
前記異なるアミノ酸が類似の化学的特性を含み、前記化学的特性が、電荷、疎水性、親水性、立体的サイズ、極性、分子構造またはその組合せからなる群より選択される、項目１９、２０または２１に記載の方法。
[項目２３]
前記異なるアミノ酸が非類似の化学的特性を含み、前記化学的特性が、電荷、疎水性、親水性、立体的サイズ、極性、分子構造またはその組合せからなる群より選択される、項目１９、２０または２１に記載の方法。
[項目２４]
前記第１のペプチドライブラリーを前記複数の親和性試薬に曝露する工程および前記少なくとも１つの親和性試薬の前記（１つまたは複数の）配列を決定する工程を１回またはそれより多くの回数繰り返すことを含む、項目１に記載の方法。
[項目２５]
前記第２のペプチドライブラリーを前記縮小された親和性試薬プールに曝露する工程および前記少なくとも１つの親和性試薬の前記（１つまたは複数の）配列を決定する工程を１回またはそれより多くの回数繰り返すことを含む、項目１に記載の方法。
[項目２６]
前記複数の親和性試薬の親和性試薬が、オリゴヌクレオチド、ペプチマー、ミニタンパク質バインダー、抗体、抗体断片またはその組合せを含む、項目１に記載の方法。
[項目２７]
前記複数の親和性試薬の親和性試薬がオリゴヌクレオチドを含む、項目１に記載の方法。
[項目２８]
第１の媒体中のペプチドライブラリー内の複数のペプチドを第２の媒体中の親和性試薬プール内の複数の親和性試薬と接触させ、ペプチド－親和性試薬複合体を形成すること、前記ペプチド－親和性試薬複合体の各々はペプチドおよび少なくとも１つの結合している親和性試薬を含み、前記ペプチドの各々はエピトープＸを含む；
前記ペプチド－親和性試薬複合体を収集すること；
未結合の親和性試薬を分離すること；ならびに
前記ペプチド－親和性試薬複合体の前記親和性試薬の（１つまたは複数の）配列を決定し、それによりエピトープＸに対する少なくとも１つの親和性試薬を同定すること
を含む、エピトープに対する親和性試薬の同定方法。
[項目２９]
前記ペプチドライブラリー内の前記ペプチドがネイティブ状態である、項目２８に記載の方法。
[項目３０]
前記ペプチドライブラリー内の前記ペプチドが非ネイティブ状態である、項目２８に記載の方法。
[項目３１]
前記非ネイティブ状態が変性状態または部分的にフォールディングされた状態である、項目２８に記載の方法。
[項目３２]
すべての工程をネイティブ状態の前記複数のペプチドで繰り返すことをさらに含む、項目３０または３１に記載の方法。
[項目３３]
前記ネイティブ状態のエピトープＸに対する前記少なくとも１つの親和性試薬が前記非ネイティブ状態のエピトープＸに対する前記少なくとも１つの親和性試薬と異なる、項目３２に記載の方法。
[項目３４]
前記ネイティブ状態のエピトープＸに対する前記少なくとも１つの親和性試薬が前記非ネイティブ状態のエピトープＸに対する前記少なくとも１つの親和性試薬と同じである、項目３２に記載の方法。
[項目３５]
前記エピトープＸが１つより多くの親和性試薬と結合する、項目２８に記載の方法。
[項目３６]
前記少なくとも１つの親和性試薬が１つより多くのエピトープと結合する、項目２８に記載の方法。
[項目３７]
前記１つより多くのエピトープが縮重アミノ酸配列を含む、項目３６に記載の方法。
[項目３８]
前記縮重アミノ酸配列は１個のアミノ酸が異なる、項目３７に記載の方法。
[項目３９]
前記縮重アミノ酸配列は１個より多くのアミノ酸が異なる、項目３７に記載の方法。
[項目４０]
前記異なるアミノ酸が類似の化学的特性を含み、前記化学的特性が、電荷、疎水性、親水性、立体的サイズ、極性、分子構造またはその組合せからなる群より選択される、項目３７、３８または３９に記載の方法。
[項目４１]
前記異なるアミノ酸が非類似の化学的特性を含み、前記化学的特性が、電荷、疎水性、親水性、立体的サイズ、極性、分子構造またはその組合せからなる群より選択される、項目３７、３８または３９に記載の方法。
[項目４２]
前記複数の親和性試薬の親和性試薬がオリゴヌクレオチドを含む、項目２８に記載の方法。
[項目４３]
前記複数のペプチドに結合された前記少なくとも１つの親和性試薬の（１つまたは複数の）配列を決定することが：
前記少なくとも１つの親和性試薬を前記複数のペプチドから分離すること；および
前記少なくとも１つの親和性試薬をシーケンシングし、それにより前記少なくとも１つの親和性試薬の前記（１つまたは複数の）配列を決定すること
を含む、項目２８に記載の方法。
[項目４４]
Ｓ
１
Ｓ
２
Ｓ
３
の構造を含む親和性試薬であって、Ｓ
１
およびＳ
３
は、相補的なアダプターに結合することができるアダプタードメインであり、Ｓ
２
はエピトープ結合ドメインであり、前記エピトープ結合ドメインは１つまたはそれより多くのペプチドエピトープに１０
－６
Ｍ未満の平衡結合定数Ｋ
ｄ
で結合する親和性試薬。
[項目４５]
前記親和性試薬がオリゴヌクレオチドを含む、項目４４に記載の親和性試薬。
[項目４６]
前記アダプタードメインが次世代シーケンシングアダプターである、項目４４に記載の親和性試薬。
[項目４７]
Ｓ
１
またはＳ
３
がバーコードを含む、項目４４に記載の親和性試薬。
[項目４８]
Ｓ
２
が約９０個以下のヌクレオチドを含む、項目４５に記載の親和性試薬。
[項目４９]
Ｓ
２
が約６０個以下のヌクレオチドを含む、項目４８に記載の親和性試薬。
[項目５０]
Ｓ
２
が約３０個以下のヌクレオチドを含む、項目４９に記載の親和性試薬。
[項目５１]
前記親和性試薬が１つより多くのエピトープに１０
－６
Ｍ未満の平衡結合定数Ｋ
ｄ
で結合する、項目４４に記載の親和性試薬。
[項目５２]
前記親和性試薬が１つまたはそれより多くのエピトープに１０
－９
Ｍ未満の平衡結合定数Ｋ
ｄ
で結合する、項目５１に記載の親和性試薬。
[項目５３]
前記親和性試薬が１つまたはそれより多くのエピトープに１０
－１２
Ｍ未満の平衡結合定数Ｋ
ｄ
で結合する、項目５２に記載の親和性試薬。
[項目５４]
前記少なくとも１つの親和性試薬が１つより多くのエピトープと結合する、項目４４に記載の親和性試薬。
[項目５５]
前記１つより多くのエピトープが縮重アミノ酸配列を含む、項目５４に記載の親和性試薬。
[項目５６]
前記縮重アミノ酸配列は１個のアミノ酸が異なる、項目５５に記載の親和性試薬。
[項目５７]
前記縮重アミノ酸配列は１個より多くのアミノ酸が異なる、項目５５に記載の親和性試薬。
[項目５８]
前記異なるアミノ酸が類似の化学的特性を含み、前記化学的特性が、電荷、疎水性、親水性、立体的サイズ、極性、分子構造またはその組合せからなる群より選択される、項目５５、５６または５７に記載の親和性試薬。
[項目５９]
前記異なるアミノ酸が非類似の化学的特性を含み、前記化学的特性が、電荷、疎水性、親水性、立体的サイズ、極性、分子構造またはその組合せからなる群より選択される、項目５５、５６または５７に記載の親和性試薬。
[項目６０]
前記親和性試薬が１つまたはそれより多くのペプチドエピトープに結合するのは前記ペプチドがネイティブ状態である場合である、項目４４に記載の親和性試薬。
[項目６１]
前記親和性試薬が１つまたはそれより多くのペプチドエピトープに結合するのは前記ペプチドが非ネイティブ状態である場合である、項目４４に記載の親和性試薬。
[項目６２]
前記非ネイティブ状態が変性状態または部分的にフォールディングされた状態を含む、項目６１に記載の親和性試薬。
[項目６３]
複数の親和性試薬を含む親和性試薬プールであって；
前記複数の親和性のうちの２つまたはそれより多くの親和性試薬が構造Ｓ
１
Ｓ
２
Ｓ
３
を含み、ここで、Ｓ
１
およびＳ
３
は共通のアダプタードメインを含み、Ｓ
２
はエピトープ結合ドメインを含む；ならびに
前記２つまたはそれより多くの親和性試薬のうちの第１の親和性試薬は、ペプチドエピトープＸ
１
に対する特性評価済みの特異性を有する第１のドメインＳ
２
を含み、前記２つまたはそれより多くの親和性試薬のうちの第２の親和性試薬は、ペプチドエピトープＸ
２
に対する特性評価済みの特異性を有する第２のドメインＳ
２
を含み、前記第１のドメインＳ
２
は前記第２のドメインＳ
２
と異なる、
親和性試薬プール。
[項目６４]
複数のペプチドを含むペプチドライブラリーを得ること、前記複数のペプチドのペプチドはその配列内に１つより多くのエピトープＸを含む；
前記ペプチドライブラリーを複数の親和性試薬を含む親和性試薬プールに曝露し、それにより少なくとも１つの親和性試薬を、その配列内に１つより多くのエピトープＸを含む前記ペプチドに結合させること；および
その配列内に１つより多くのエピトープＸを含む前記ペプチドに結合された前記少なくとも１つの親和性試薬の（１つまたは複数の）配列を決定し、それによりエピトープＸに対する親和性試薬を同定すること
を含む、エピトープに対する親和性試薬の同定方法。
249. 248. The affinity reagent pool of item 248, wherein the liquid medium comprises an aqueous medium.
The disclosure provided herein is also defined by the following items:
[Item 1]
Obtaining a first peptide library comprising a first plurality of peptides, each peptide comprising a sequence of the formula αXβ, where X is a desired epitope and α and β are peptides comprising known amino acid sequences; is a ranking domain;
exposing said first peptide library to a plurality of affinity reagents, thereby allowing at least one affinity reagent of said plurality of affinity reagents to bind to said first peptide library;
determining the sequence(s) of said at least one affinity reagent bound to said first plurality of peptides, thereby forming a reduced affinity reagent pool;
obtaining a second peptide library comprising a second plurality of peptides, each peptide comprising a sequence of the formula γXδ, where X is the desired epitope and γ and δ are frames comprising known amino acid sequences; is a ranking domain;
exposing said second peptide library to said reduced affinity reagent pool, thereby allowing at least one affinity reagent of said reduced affinity reagent pool to bind to said second peptide library; and
determining the sequence(s) of at least one affinity reagent bound to said second peptide library in said reduced affinity reagent pool, thereby identifying affinity reagents for said epitope X; to identify
A method of identifying an affinity reagent for an epitope, comprising:
[Item 2]
The method of item 1, wherein α and β comprise the same amino acid sequence.
[Item 3]
The method of item 1, wherein α and β comprise different amino acid sequences.
[Item 4]
The method of item 1, wherein α and β comprise amino acid sequences different from γ and δ.
[Item 5]
The method of item 1, wherein α and β comprise amino acid sequences with homogeneous chemical diversity.
[Item 6]
An amino acid in which the amino acid sequence with homogeneous chemical diversity comprises two or more amino acid side chain groups with equivalent charge, hydrophobicity, hydrophilicity, steric size, polarity, molecular structure, or a combination thereof 6. The method of item 5, comprising a sequence.
[Item 7]
The method of item 1, wherein α and β comprise amino acid sequences with heterogeneous chemical diversity.
[Item 8]
Amino acids in which said heterogeneous chemically diverse amino acid sequence comprises two or more amino acid side chain groups having different charge, hydrophobicity, hydrophilicity, steric size, polarity, molecular structure or a combination thereof. A method according to item 7, comprising a sequence.
[Item 9]
The method of item 1, wherein γ and δ comprise amino acid sequences with homogeneous chemical diversity.
[Item 10]
An amino acid in which the amino acid sequence with homogeneous chemical diversity comprises two or more amino acid side chain groups with equivalent charge, hydrophobicity, hydrophilicity, steric size, polarity, molecular structure, or a combination thereof 10. The method of item 9, comprising a sequence.
[Item 11]
The method of item 1, wherein γ and δ comprise amino acid sequences with heterogeneous chemical diversity.
[Item 12]
Amino acids in which said heterogeneous chemically diverse amino acid sequence comprises two or more amino acid side chain groups having different charge, hydrophobicity, hydrophilicity, steric size, polarity, molecular structure or a combination thereof. 12. The method of item 11, comprising a sequence.
[Item 13]
2. The method of item 1, further comprising washing said at least one affinity reagent bound to said first peptide library among said plurality of affinity reagents.
[Item 14]
2. The method of item 1, further comprising washing said at least one affinity reagent bound to said second peptide library among said reduced affinity reagent pool.
[Item 15]
2. The method of item 1, wherein said peptides in said first or second peptide library are in their native state.
[Item 16]
2. The method of item 1, wherein said peptides in said first or second library of peptides are in a non-native state.
[Item 17]
A method according to item 1, wherein said non-native state is an denatured or partially folded state.
[Item 18]
2. The method of item 1, wherein said at least on affinity reagent binds to more than one epitope.
[Item 19]
19. The method of item 18, wherein said more than one epitope comprises a degenerate amino acid sequence.
[Item 20]
20. The method of item 19, wherein the degenerate amino acid sequences differ by one amino acid.
[Item 21]
20. The method of item 19, wherein said degenerate amino acid sequences differ by more than one amino acid.
[Item 22]
Item 19, 20, or wherein said different amino acids comprise similar chemical properties, said chemical properties being selected from the group consisting of charge, hydrophobicity, hydrophilicity, steric size, polarity, molecular structure or combinations thereof. 21. The method according to 21.
[Item 23]
Items 19, 20, wherein said different amino acids comprise dissimilar chemical properties, said chemical properties being selected from the group consisting of charge, hydrophobicity, hydrophilicity, steric size, polarity, molecular structure or combinations thereof. or the method according to 21.
[Item 24]
repeating the steps of exposing said first peptide library to said plurality of affinity reagents and determining said sequence(s) of said at least one affinity reagent one or more times The method of item 1, comprising:
[Item 25]
exposing said second peptide library to said reduced affinity reagent pool and determining said sequence(s) of said at least one affinity reagent; The method of item 1, comprising repeating a number of times.
[Item 26]
The method of item 1, wherein the affinity reagents of said plurality of affinity reagents comprise oligonucleotides, peptimers, mini-protein binders, antibodies, antibody fragments or combinations thereof.
[Item 27]
2. The method of item 1, wherein affinity reagents of said plurality of affinity reagents comprise oligonucleotides.
[Item 28]
contacting a plurality of peptides in a peptide library in a first medium with a plurality of affinity reagents in an affinity reagent pool in a second medium to form peptide-affinity reagent complexes; - each of the affinity reagent conjugates comprises a peptide and at least one bound affinity reagent, each of said peptides comprising epitope X;
collecting said peptide-affinity reagent complex;
separating unbound affinity reagent; and
determining the sequence(s) of said affinity reagent(s) of said peptide-affinity reagent complex, thereby identifying at least one affinity reagent for epitope X;
A method of identifying an affinity reagent for an epitope, comprising:
[Item 29]
29. The method of item 28, wherein said peptides in said peptide library are in their native state.
[Item 30]
29. The method of item 28, wherein said peptide in said peptide library is in a non-native state.
[Item 31]
29. The method of item 28, wherein said non-native state is an denatured or partially folded state.
[Item 32]
32. The method of item 30 or 31, further comprising repeating all steps with said plurality of peptides in their native state.
[Item 33]
33. Method according to item 32, wherein said at least one affinity reagent for said native state epitope X is different from said at least one affinity reagent for said non-native state epitope X.
[Item 34]
33. The method of item 32, wherein said at least one affinity reagent for said native state epitope X is the same as said at least one affinity reagent for said non-native state epitope X.
[Item 35]
29. The method of item 28, wherein said epitope X binds to more than one affinity reagent.
[Item 36]
29. The method of item 28, wherein said at least one affinity reagent binds to more than one epitope.
[Item 37]
37. The method of item 36, wherein said more than one epitope comprises a degenerate amino acid sequence.
[Item 38]
38. The method of item 37, wherein said degenerate amino acid sequences differ by one amino acid.
[Item 39]
38. The method of item 37, wherein said degenerate amino acid sequences differ by more than one amino acid.
[Item 40]
item 37, 38, wherein said different amino acids comprise similar chemical properties, said chemical properties being selected from the group consisting of charge, hydrophobicity, hydrophilicity, steric size, polarity, molecular structure or combinations thereof; 39. The method according to 39.
[Item 41]
Items 37, 38, wherein said different amino acids comprise dissimilar chemical properties, said chemical properties being selected from the group consisting of charge, hydrophobicity, hydrophilicity, steric size, polarity, molecular structure or combinations thereof. Or the method according to 39.
[Item 42]
29. The method of item 28, wherein affinity reagents of said plurality of affinity reagents comprise oligonucleotides.
[Item 43]
Determining the sequence(s) of said at least one affinity reagent bound to said plurality of peptides:
separating said at least one affinity reagent from said plurality of peptides; and
sequencing said at least one affinity reagent thereby determining said sequence(s) of said at least one affinity reagent
29. The method of item 28, comprising
[Item 44]
An affinity reagent comprising the structure S 1 S 2 S 3 , wherein S 1 and S 3 are adapter domains capable of binding to complementary adapters, S 2 is an epitope binding domain, and said epitope A binding domain is an affinity reagent that binds one or more peptide epitopes with an equilibrium binding constant K d of less than 10 −6 M.
[Item 45]
45. The affinity reagent of item 44, wherein said affinity reagent comprises an oligonucleotide.
[Item 46]
45. The affinity reagent of item 44, wherein said adapter domain is a next generation sequencing adapter.
[Item 47]
45. The affinity reagent of item 44 , wherein S1 or S3 comprises a barcode.
[Item 48]
46. The affinity reagent of item 45, wherein S2 comprises about 90 nucleotides or less.
[Item 49]
49. The affinity reagent of item 48, wherein S2 comprises about 60 nucleotides or less.
[Item 50]
50. The affinity reagent of item 49, wherein S2 comprises about 30 or fewer nucleotides.
[Item 51]
45. The affinity reagent of item 44, wherein said affinity reagent binds to more than one epitope with an equilibrium binding constant K d of less than 10 −6 M.
[Item 52]
52. The affinity reagent of item 51, wherein said affinity reagent binds to one or more epitopes with an equilibrium binding constant K d of less than 10 −9 M.
[Item 53]
53. The affinity reagent of item 52, wherein said affinity reagent binds to one or more epitopes with an equilibrium binding constant K d of less than 10 −12 M.
[Item 54]
45. Affinity reagent according to item 44, wherein said at least one affinity reagent binds more than one epitope.
[Item 55]
55. The affinity reagent of item 54, wherein said more than one epitope comprises a degenerate amino acid sequence.
[Item 56]
56. The affinity reagent of item 55, wherein said degenerate amino acid sequences differ by one amino acid.
[Item 57]
56. The affinity reagent of item 55, wherein said degenerate amino acid sequences differ by more than one amino acid.
[Item 58]
item 55, 56, wherein said different amino acids comprise similar chemical properties, said chemical properties being selected from the group consisting of charge, hydrophobicity, hydrophilicity, steric size, polarity, molecular structure or combinations thereof; 57. Affinity reagent according to 57.
[Item 59]
Items 55, 56, wherein said different amino acids comprise dissimilar chemical properties, said chemical properties being selected from the group consisting of charge, hydrophobicity, hydrophilicity, steric size, polarity, molecular structure or combinations thereof. or the affinity reagent according to 57.
[Item 60]
45. The affinity reagent of item 44, wherein said affinity reagent binds to one or more peptide epitopes when said peptide is in its native state.
[Item 61]
45. The affinity reagent of item 44, wherein said affinity reagent binds to one or more peptide epitopes when said peptide is in a non-native state.
[Item 62]
62. The affinity reagent of item 61, wherein said non-native state comprises a denatured or partially folded state.
[Item 63]
an affinity reagent pool comprising a plurality of affinity reagents;
Two or more affinity reagents of said plurality of affinities comprise the structure S 1 S 2 S 3 , where S 1 and S 3 comprise a common adapter domain and S 2 is an epitope binding contains a domain; and
a first affinity reagent of said two or more affinity reagents comprises a first domain S2 with characterized specificity for peptide epitope X1 ; A second affinity reagent of a number of affinity reagents comprises a second domain S2 with characterized specificity for peptide epitope X2 , said first domain S2 different from domain S2 ,
Affinity reagent pool.
[Item 64]
obtaining a peptide library comprising a plurality of peptides, wherein the peptides of said plurality of peptides contain more than one epitope X within their sequence;
exposing said peptide library to an affinity reagent pool comprising a plurality of affinity reagents, thereby binding at least one affinity reagent to said peptides containing more than one epitope X within their sequence; and
determining the sequence(s) of said at least one affinity reagent bound to said peptide containing more than one epitope X within its sequence, thereby identifying affinity reagents to epitope X thing
A method of identifying an affinity reagent for an epitope, comprising:
Claims (28)
前記第１のペプチドライブラリーを複数の親和性試薬に曝露し、それにより前記複数の親和性試薬の少なくとも１つの親和性試薬を前記第１のペプチドライブラリーに結合させること；
第１の複数のペプチドに結合する、前記少なくとも１つの親和性試薬を含む、縮小された親和性試薬プールを形成すること；
各ペプチドが式γＸδの配列を含む第２の複数のペプチドを含む第２のペプチドライブラリーを得ること、式中、Ｘは所望のエピトープであり、γおよびδは、既知のアミノ酸配列を含むフランキングドメインである；
前記第２のペプチドライブラリーを前記縮小された親和性試薬プールに曝露し、それにより前記縮小された親和性試薬プールの少なくとも１つの親和性試薬を前記第２のペプチドライブラリーに結合させること；ならびに
前記縮小された親和性試薬プールのうち前記第２のペプチドライブラリーに結合された少なくとも１つの親和性試薬の（１つまたは複数の）配列を決定し、それにより前記エピトープＸに対する親和性試薬を同定すること
を含む、エピトープに対する親和性試薬の同定方法。 Obtaining a first peptide library comprising a first plurality of peptides, each peptide comprising a sequence of the formula αXβ, where X is a desired epitope and α and β are peptides comprising known amino acid sequences; is a ranking domain;
exposing said first peptide library to a plurality of affinity reagents, thereby allowing at least one affinity reagent of said plurality of affinity reagents to bind to said first peptide library;
forming a reduced affinity reagent pool comprising said at least one affinity reagent that binds to the first plurality of peptides ;
obtaining a second peptide library comprising a second plurality of peptides, each peptide comprising a sequence of the formula γXδ, where X is the desired epitope and γ and δ are frames comprising known amino acid sequences; is a ranking domain;
exposing said second peptide library to said reduced affinity reagent pool, thereby allowing at least one affinity reagent of said reduced affinity reagent pool to bind to said second peptide library; and determining the sequence(s) of at least one affinity reagent bound to said second peptide library in said reduced affinity reagent pool, thereby affinity reagent to said epitope X. A method of identifying an affinity reagent for an epitope, comprising identifying an epitope.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862770136P | 2018-11-20 | 2018-11-20 | |
| US62/770,136 | 2018-11-20 | ||
| PCT/US2019/062482 WO2020106889A1 (en) | 2018-11-20 | 2019-11-20 | Design and selection of affinity reagents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513092A JP2022513092A (en) | 2022-02-07 |
| JPWO2020106889A5 true JPWO2020106889A5 (en) | 2022-11-24 |
Family
ID=70773190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527883A Pending JP2022513092A (en) | 2018-11-20 | 2019-11-20 | Design and selection of affinity reagents |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11993865B2 (en) |
| EP (1) | EP3884048A4 (en) |
| JP (1) | JP2022513092A (en) |
| CN (1) | CN113316638A (en) |
| WO (1) | WO2020106889A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018102759A1 (en) | 2016-12-01 | 2018-06-07 | Ignite Biosciences, Inc. | Methods of assaying proteins |
| EP3669018A4 (en) | 2017-08-18 | 2021-05-26 | Nautilus Biotechnology, Inc. | Methods of selecting binding reagents |
| CA3079832A1 (en) * | 2017-10-23 | 2019-05-02 | Nautilus Biotechnology, Inc. | Methods and systems for protein identification |
| WO2019195633A1 (en) | 2018-04-04 | 2019-10-10 | Ignite Biosciences, Inc. | Methods of generating nanoarrays and microarrays |
| CN113316638A (en) | 2018-11-20 | 2021-08-27 | 诺迪勒思生物科技公司 | Design and selection of affinity reagents |
| US11692217B2 (en) | 2020-11-11 | 2023-07-04 | Nautilus Subsidiary, Inc. | Affinity reagents having enhanced binding and detection characteristics |
| US20220236282A1 (en) | 2021-01-20 | 2022-07-28 | Nautilus Biotechnology, Inc. | Systems and methods for biomolecule quantitation |
| WO2022192591A1 (en) | 2021-03-11 | 2022-09-15 | Nautilus Biotechnology, Inc. | Systems and methods for biomolecule retention |
| WO2023049073A1 (en) | 2021-09-22 | 2023-03-30 | Nautilus Biotechnology, Inc. | Methods and systems for determining polypeptide interactions |
| WO2023083323A1 (en) * | 2021-11-12 | 2023-05-19 | The Hong Kong University Of Science And Technology | A peptide and the selection method thereof |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US6589726B1 (en) | 1991-09-04 | 2003-07-08 | Metrigen, Inc. | Method and apparatus for in situ synthesis on a solid support |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| US5512492A (en) | 1993-05-18 | 1996-04-30 | University Of Utah Research Foundation | Waveguide immunosensor with coating chemistry providing enhanced sensitivity |
| US5635602A (en) | 1993-08-13 | 1997-06-03 | The Regents Of The University Of California | Design and synthesis of bispecific DNA-antibody conjugates |
| US6682886B1 (en) | 1994-04-28 | 2004-01-27 | Gilead Sciences, Inc. | Bivalent binding molecules of 7 transmembrane G protein-coupled receptors |
| US5695934A (en) | 1994-10-13 | 1997-12-09 | Lynx Therapeutics, Inc. | Massively parallel sequencing of sorted polynucleotides |
| US5888737A (en) | 1997-04-15 | 1999-03-30 | Lynx Therapeutics, Inc. | Adaptor-based sequence analysis |
| US5919626A (en) | 1997-06-06 | 1999-07-06 | Orchid Bio Computer, Inc. | Attachment of unmodified nucleic acids to silanized solid phase surfaces |
| CA2339121A1 (en) | 1998-07-30 | 2000-02-10 | Shankar Balasubramanian | Arrayed biomolecules and their use in sequencing |
| US6824866B1 (en) | 1999-04-08 | 2004-11-30 | Affymetrix, Inc. | Porous silica substrates for polymer synthesis and assays |
| KR100379411B1 (en) | 1999-06-28 | 2003-04-10 | 엘지전자 주식회사 | biochip and method for patterning and measuring biomaterial of the same |
| WO2001046675A2 (en) | 1999-12-23 | 2001-06-28 | Illumina, Inc. | Decoding of array sensors with microspheres |
| US6806361B1 (en) | 2000-03-17 | 2004-10-19 | Affymetrix, Inc. | Methods of enhancing functional performance of nucleic acid arrays |
| US7148058B2 (en) | 2000-06-05 | 2006-12-12 | Chiron Corporation | Protein microarrays on mirrored surfaces for performing proteomic analyses |
| US7158224B2 (en) | 2000-06-25 | 2007-01-02 | Affymetrix, Inc. | Optically active substrates |
| GB2388945B (en) | 2000-10-27 | 2004-12-15 | Fulcit New Zealand Ltd | Method and apparatus for generating an alert message |
| US20030054408A1 (en) | 2001-04-20 | 2003-03-20 | Ramamoorthi Ravi | Methods and systems for identifying proteins |
| US6720595B2 (en) | 2001-08-06 | 2004-04-13 | International Business Machines Corporation | Three-dimensional island pixel photo-sensor |
| EP1457782A1 (en) | 2001-11-22 | 2004-09-15 | Riken | Substrate for biomolecule microarray, process for producing the same, biomolecule microarray and method of collecting data on biomolecule microarray |
| WO2003046144A2 (en) | 2001-11-26 | 2003-06-05 | Molecular Reflections, Inc. | Microscale immobilization of molecules using a hydrogel and methods of use thereof |
| US20050054118A1 (en) | 2002-02-27 | 2005-03-10 | Lebrun Stewart J. | High throughput screening method |
| KR100455293B1 (en) | 2002-05-15 | 2004-11-06 | 삼성전자주식회사 | A process for producing array plate for a biomolecule comprising a hydrophilic region and a hydrophobic region |
| US6998241B2 (en) | 2002-09-11 | 2006-02-14 | Kimberly-Clark Worldwide, Inc. | Antibody pair screening methods |
| CA2502246A1 (en) | 2002-10-15 | 2004-04-29 | Abmetrix, Inc. | Sets of digital antibodies directed against short epitopes, and methods using same |
| US20050196808A1 (en) | 2002-11-14 | 2005-09-08 | Yaffe Michael B. | Products and processes for modulating peptide-peptide binding domain interactions |
| US20040209383A1 (en) | 2003-04-17 | 2004-10-21 | Industrial Technology Research Institute | Lift-off process for protein chip |
| TWI375796B (en) | 2003-04-18 | 2012-11-01 | Becton Dickinson Co | Immuno-amplification |
| EP1642114A1 (en) | 2003-06-25 | 2006-04-05 | Koninklijke Philips Electronics N.V. | Support with a surface structure for sensitive evanescent-field detection |
| US20050095577A1 (en) | 2003-10-31 | 2005-05-05 | Yang Dan-Hui D. | Protein bioarray on silane-modified substrate surface |
| US7635562B2 (en) | 2004-05-25 | 2009-12-22 | Helicos Biosciences Corporation | Methods and devices for nucleic acid sequence determination |
| US20050287523A1 (en) | 2004-06-01 | 2005-12-29 | The Regents Of The University Of California | Functionalized platform for individual molecule or cell characterization |
| US20060160234A1 (en) | 2005-01-18 | 2006-07-20 | Viorica Lopez-Avila | Methods for assessing polypeptide array quality |
| AU2006227380B2 (en) | 2005-03-17 | 2012-08-16 | Vel Partners Holdings Llc | Immunogens for vaccines against antigenically variable pathogens and diseases |
| GB0507835D0 (en) | 2005-04-18 | 2005-05-25 | Solexa Ltd | Method and device for nucleic acid sequencing using a planar wave guide |
| WO2006122002A2 (en) | 2005-05-09 | 2006-11-16 | Panomics, Inc. | Multiplex capture of nucleic acids |
| WO2006135527A2 (en) * | 2005-06-10 | 2006-12-21 | Saint Louis University | Methods for the selection of aptamers |
| US7842793B2 (en) | 2005-06-14 | 2010-11-30 | The California Institute Of Technology | Methods of making nucleic acid nanostructures |
| DK1907583T4 (en) | 2005-06-15 | 2020-01-27 | Complete Genomics Inc | SINGLE MOLECULE ARRAYS FOR GENETIC AND CHEMICAL ANALYSIS |
| WO2007056490A2 (en) | 2005-11-08 | 2007-05-18 | Incom, Inc. | Fiber optic interrogated microslide, microslide kits and uses thereof |
| WO2007120208A2 (en) | 2005-11-14 | 2007-10-25 | President And Fellows Of Harvard College | Nanogrid rolling circle dna sequencing |
| US20070218503A1 (en) | 2006-02-13 | 2007-09-20 | Mitra Robi D | Methods of polypeptide identification, and compositions therefor |
| US7692783B2 (en) | 2006-02-13 | 2010-04-06 | Pacific Biosciences Of California | Methods and systems for simultaneous real-time monitoring of optical signals from multiple sources |
| CN100500865C (en) | 2006-04-21 | 2009-06-17 | 华东师范大学 | Method for detecting CatD protein by identifying a plurality of epitopes synchronously |
| US8241573B2 (en) | 2006-03-31 | 2012-08-14 | Illumina, Inc. | Systems and devices for sequence by synthesis analysis |
| WO2007117444A2 (en) | 2006-03-31 | 2007-10-18 | Yinghe Hu | Protein detection by aptamers |
| WO2008045252A2 (en) | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
| WO2009012340A2 (en) | 2007-07-16 | 2009-01-22 | California Institute Of Technology | Microfluidic devices, methods and systems for detecting target molecules |
| US7811810B2 (en) | 2007-10-25 | 2010-10-12 | Industrial Technology Research Institute | Bioassay system including optical detection apparatuses, and method for detecting biomolecules |
| AU2009234373B2 (en) | 2008-04-09 | 2015-09-24 | Cornell University | Coferons and methods of making and using them |
| US9340416B2 (en) | 2008-08-13 | 2016-05-17 | California Institute Of Technology | Polynucleotides and related nanoassemblies, structures, arrangements, methods and systems |
| WO2010065531A1 (en) | 2008-12-01 | 2010-06-10 | Robi David Mitra | Single molecule protein screening |
| WO2010073605A1 (en) | 2008-12-24 | 2010-07-01 | 株式会社日立ハイテクノロジーズ | Fluorescence detector |
| US8603792B2 (en) | 2009-03-27 | 2013-12-10 | Life Technologies Corporation | Conjugates of biomolecules to nanoparticles |
| WO2010120385A1 (en) | 2009-04-18 | 2010-10-21 | Massachusetts Institute Of Technology | pH SENSITIVE BIODEGRADABLE POLYMERIC PARTICLES FOR DRUG DELIVERY |
| EP2933629B1 (en) | 2010-02-19 | 2019-04-10 | Pacific Biosciences Of California, Inc. | System for measuring analytical reactions comprising a socket for an optode array chip |
| US8865077B2 (en) | 2010-06-11 | 2014-10-21 | Industrial Technology Research Institute | Apparatus for single-molecule detection |
| US9523680B2 (en) | 2010-06-30 | 2016-12-20 | Ambergen, Inc. | Global Proteomic screening of random bead arrays using mass spectrometry imaging |
| US8951781B2 (en) | 2011-01-10 | 2015-02-10 | Illumina, Inc. | Systems, methods, and apparatuses to image a sample for biological or chemical analysis |
| CN102618940A (en) | 2011-01-31 | 2012-08-01 | 艾比玛特生物医药（上海）有限公司 | Antibody preparation method and obtained antibody and antibody database |
| CN204832037U (en) | 2012-04-03 | 2015-12-02 | 伊鲁米那股份有限公司 | Detection apparatus |
| NL2009191C2 (en) | 2012-07-16 | 2014-01-20 | Univ Delft Tech | Single molecule protein sequencing. |
| CA3178340A1 (en) | 2012-08-20 | 2014-02-27 | Illumina, Inc. | Method and system for fluorescence lifetime based sequencing |
| MX2015006219A (en) | 2012-11-19 | 2015-11-13 | Apton Biosystems Inc | Digital analysis of molecular analytes using single molecule detection. |
| US10829816B2 (en) | 2012-11-19 | 2020-11-10 | Apton Biosystems, Inc. | Methods of analyte detection |
| AU2014348305B2 (en) | 2013-11-17 | 2020-10-01 | Quantum-Si Incorporated | Integrated device with external light source for probing detecting and analyzing molecules |
| RU2687847C1 (en) | 2013-12-03 | 2019-05-16 | Конинклейке Филипс Н.В. | Biosensor comprising waveguide |
| DK3087083T3 (en) | 2013-12-27 | 2019-12-16 | Hoffmann La Roche | Systemic discovery, maturation and extension of peptide binders to proteins |
| US20170212101A1 (en) | 2014-07-18 | 2017-07-27 | Cdi Laboratories, Inc. | Methods and compositions to identify, quantify, and characterize target analytes and binding moieties |
| KR102585730B1 (en) | 2014-08-08 | 2023-10-10 | 퀀텀-에스아이 인코포레이티드 | Integrated device for temporal binning of received photons |
| KR102472061B1 (en) | 2014-08-08 | 2022-11-29 | 퀀텀-에스아이 인코포레이티드 | Optical system and assay chip for probing, detecting, and analyzing molecules |
| CN112903638A (en) | 2014-08-08 | 2021-06-04 | 宽腾矽公司 | Integrated device with external light source for detection, detection and analysis of molecules |
| EP3009520B1 (en) | 2014-10-14 | 2018-12-12 | Karlsruher Institut für Technologie | Site-specific immobilization of DNA origami structures on solid substrates |
| JP6390408B2 (en) | 2014-12-16 | 2018-09-19 | 富士ゼロックス株式会社 | Image forming apparatus and program |
| EP3274473B1 (en) | 2015-03-24 | 2020-10-28 | Pacific Biosciences of California, Inc. | Methods and compositions for single molecule composition loading |
| US9881786B2 (en) | 2015-04-02 | 2018-01-30 | Micron Technology, Inc. | Methods of forming nanostructures using self-assembled nucleic acids, and nanostructures thereof |
| WO2016174525A1 (en) | 2015-04-29 | 2016-11-03 | Biosims Technologies | Enhanced sensitivity in ligand binding assays performed with secondary ion mass spectrometry |
| US10605730B2 (en) | 2015-05-20 | 2020-03-31 | Quantum-Si Incorporated | Optical sources for fluorescent lifetime analysis |
| WO2017127762A1 (en) * | 2016-01-20 | 2017-07-27 | Vitrisa Therapeutics, Inc. | Methods for improved aptamer selection |
| WO2018102759A1 (en) | 2016-12-01 | 2018-06-07 | Ignite Biosciences, Inc. | Methods of assaying proteins |
| MX2019007530A (en) | 2016-12-22 | 2019-08-16 | Quantum Si Inc | Integrated photodetector with direct binning pixel. |
| EP3669018A4 (en) | 2017-08-18 | 2021-05-26 | Nautilus Biotechnology, Inc. | Methods of selecting binding reagents |
| US11125748B2 (en) | 2017-09-01 | 2021-09-21 | University Of British Columbia | Method for organizing individual molecules on a patterned substrate and structures assembled thereby |
| US11391734B2 (en) | 2017-09-25 | 2022-07-19 | California Institute Of Technology | Surface-immobilized bistable polynucleotide devices for the sensing and quantification of molecular events |
| AU2018358247A1 (en) | 2017-10-31 | 2020-05-21 | Encodia, Inc. | Methods and kits using nucleic acid encoding and/or label |
| DK3498865T3 (en) | 2017-12-14 | 2020-12-21 | Univ Muenchen Ludwig Maximilians | Detection and quantification of single molecules using DNA nanotechnology in microwells |
| WO2019195633A1 (en) | 2018-04-04 | 2019-10-10 | Ignite Biosciences, Inc. | Methods of generating nanoarrays and microarrays |
| US20210239705A1 (en) | 2018-06-06 | 2021-08-05 | Nautilus Biotechnology, Inc. | Methods and applications of protein identification |
| CN113316638A (en) | 2018-11-20 | 2021-08-27 | 诺迪勒思生物科技公司 | Design and selection of affinity reagents |
| US20210399030A1 (en) | 2018-12-01 | 2021-12-23 | Mgi Tech Co., Ltd. | Methods and structures to improve light collection efficiency in biosensors |
| WO2020223368A1 (en) | 2019-04-29 | 2020-11-05 | Nautilus Biotechnology, Inc. | Methods and systems for integrated on-chip single-molecule detection |
-
2019
- 2019-11-20 CN CN201980089624.6A patent/CN113316638A/en active Pending
- 2019-11-20 EP EP19886855.6A patent/EP3884048A4/en active Pending
- 2019-11-20 JP JP2021527883A patent/JP2022513092A/en active Pending
- 2019-11-20 WO PCT/US2019/062482 patent/WO2020106889A1/en unknown
- 2019-11-20 US US17/424,435 patent/US11993865B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Weng et al. | Generating addressable protein microarrays with PROfusion™ covalent mRNA‐protein fusion technology | |
| JPS62502568A (en) | Improved method for mimotope determination | |
| JPWO2020106889A5 (en) | ||
| JP5753775B2 (en) | Methods and compositions for measuring the purity of chemically synthesized nucleic acids | |
| JPH05508701A (en) | Methods for identifying ligands that bind to analytes | |
| JPS61502839A (en) | How to detect or determine mimotopes | |
| JP2005514030A5 (en) | ||
| JP2010501552A (en) | Affinity separation method in aqueous two-phase extraction method using biological material conjugated with partition enhancing substance | |
| US8318440B2 (en) | Synthetic peptides immuno-reactive with rheumatoid arthritis auto-antibodies | |
| Barbas et al. | Recognition of DNA by synthetic antibodies | |
| US20060263787A1 (en) | Immunoglobulin-like variable chain binding polypeptides and methods of use | |
| CN111511768B (en) | mRNA display antibody libraries and methods | |
| CA2268397C (en) | Magnetically activated cell sorting for production of proteins | |
| WO1998016541A9 (en) | Magnetically activated cell sorting for production of proteins | |
| WO1993024630A1 (en) | Reagent for agglutination assays | |
| JP5208813B2 (en) | Methods and compositions for determining the purity of chemically synthesized nucleic acids and purifying chemically synthesized nucleic acids | |
| Gilbert et al. | Double chip protein arrays using recombinant single‐chain Fv antibody fragments | |
| JP2018027024A (en) | Detection method of aptamer and antibody | |
| Tu et al. | Combinatorial search for diagnostic agents: Lyme antibody H9724 as an example | |
| Morris | Epitope mapping | |
| AU2002318434A1 (en) | Methods and compositions for determining the purity of and purifying chemically synthesized nucleic acids | |
| Kramer et al. | Antibodies for biosensors | |
| Han et al. | Reusable immunomagnetic beads in an enzyme immunoassay | |
| AU684715B2 (en) | Reagent for agglutination assays | |
| US20100324215A1 (en) | Affinity structures for the specific binding of substances by means of non-covalent interaction types |